ISPC vs BRLT vs MEDP vs ICLR vs CRL

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -79. 2% for iSpecimen Inc. (ISPC). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate ICON Public Limited Company (ICLR) a "Buy" — based on 30 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Medpace Holdings, Inc. at 27. 7x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 78x versus ICON Public Limited Company's 1. 53x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +167. 0%, compared to -99. 9% for iSpecimen Inc. (ISPC). Over 10 years, the gap is even starker: MEDP returned +1426% versus ISPC's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Brilliant Earth Group, Inc.

(BRLT) is the lower-risk stock at 1. 14β versus ICON Public Limited Company's 1. 64β — meaning ICLR is approximately 43% more volatile than BRLT relative to the S&P 500. On balance sheet safety, iSpecimen Inc. (ISPC) carries a lower debt/equity ratio of 9% versus 95% for Charles River Laboratories International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -79. 2% for iSpecimen Inc. (ISPC). On earnings-per-share growth, the picture is similar: iSpecimen Inc. grew EPS 87. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -543. 7% for iSpecimen Inc. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -465. 4% for ISPC. At the gross margin level — before operating expenses — BRLT leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 78x versus ICON Public Limited Company's 1. 53x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10. 7x forward P/E versus 47. 7x for Brilliant Earth Group, Inc. — 36. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ICLR: 22. 2% to $152. 13.

In this comparison, BRLT (1.

8% yield) pays a dividend. ISPC, MEDP, ICLR, CRL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), +1426% 10Y return). iSpecimen Inc. (ISPC) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1426%, ISPC: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ISPC (Healthcare) and BRLT (Consumer Cyclical) and MEDP (Healthcare) and ICLR (Healthcare) and CRL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ISPC is a small-cap quality compounder stock; BRLT is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; ICLR is a small-cap deep-value stock; CRL is a small-cap quality compounder stock. BRLT pays a dividend while ISPC, MEDP, ICLR, CRL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.